To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Directorate change

Release Date: 16/01/2020 16:00
Code(s): MEI
 
Wrap Text
Directorate change

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)

16 January 2020

DIRECTORATE CHANGE

SEAMUS KEATING TO STEP DOWN AS NON-EXECUTIVE DIRECTOR

The Company announces that Seamus Keating, who serves as an independent non-executive
director and member of the Audit and Risk Committee, Remuneration Committee and Clinical
Performance and Sustainability Committee, will step down from the board of Mediclinic at a
date to be agreed in due course. This follows Mr Keating’s appointment as Chief Executive
Officer of First Derivatives plc with effect from 15 January 2020. The Board will shortly
commence a process to identify a suitable replacement for Mr Keating, with an announcement
to follow accordingly. Mr Keating will continue to discharge his current Mediclinic responsibilities
in the meantime.

Dr Edwin Hertzog, Chairman of Mediclinic, commented:

“On behalf of my colleagues on the Board, I would like to thank Seamus for his commitment
and valued contributions to the Board and the Group over the past seven years. We wish him
well as he commences his new demanding role.”

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United
Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
As at 30 November 2019, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 13 day
case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics
and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic
Southern Africa operations included 53 hospitals (three of which in Namibia), five sub-acute
hospitals and nine day case clinics (four of which operated by Intercare) across South Africa,
and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two
day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab
Emirates.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United
Kingdom, with secondary listings on the JSE Ltd ("JSE") in South Africa and the Namibian
Stock Exchange ("NSX") in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 16-01-2020 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story